Hainan General Hospital
14
6
7
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
29%
4 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Clinical Trial of BAO-G Technique in Complex Aortic Aneurysm Endovascular Repair (BAO-G-02)
Role: collaborator
Artificial Intelligence-assisted Diagnosis
Role: collaborator
HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
Role: collaborator
Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major
Role: collaborator
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Role: collaborator
Manual Acupuncture (MA) for Asymptomatic Hyperuricemia (HUA)
Role: collaborator
Clinical Study of Genakumab for Injection in Patients With Acute Gout
Role: collaborator
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
Role: collaborator
Constant Current Versus Constant Voltage Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease
Role: collaborator
Real-world Study Optimizing Nucleotide-analogues
Role: collaborator
DEB-TACE+HAIC vs. HAIC for Large HCC
Role: collaborator
Time Window for Ischemic Stroke First Mobilization Effectiveness
Role: collaborator
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
Role: collaborator
A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B
Role: collaborator
All 14 trials loaded